LON:GNS Genus (GNS) Share Forecast, Price & News GBX 2,074 -10.00 (-0.48%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range 2,072▼ 2,10650-Day Range 2,068▼ 2,50652-Week Range 2,050▼ 3,364Volume110,965 shsAverage Volume112,242 shsMarket Capitalization£1.37 billionP/E Ratio4,148.00Dividend Yield1.54%Price TargetGBX 4,500 ProfileProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlines Genus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.0% UpsideGBX 4,500 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingSelling Shares£11.23 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 4,500, Genus has a forecasted upside of 117.0% from its current price of GBX 2,074.Amount of Analyst CoverageGenus has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GNS. Previous Next 0.8 Dividend Strength Dividend YieldGenus pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 6,400.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNS. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 30 people have searched for GNS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Genus to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genus insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £112,262.22 in company stock.Percentage Held by InsidersOnly 0.67% of the stock of Genus is held by insiders.Percentage Held by Institutions78.56% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 4,148.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 115.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 4,148.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 111.77.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genus (LON:GNS) StockGenus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.Read More GNS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNS Stock News HeadlinesSeptember 16, 2023 | americanbankingnews.comGenus plc (LON:GNS) Insider Stephen Wilson Sells 5,241 SharesSeptember 7, 2023 | msn.comWhy You Should Grow Native Plants in Your GardenSeptember 23, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 7, 2023 | finance.yahoo.comGenus plc Preliminary Results for the Year Ended 30 June 2023September 5, 2023 | benzinga.comThinking about buying stock in Scilex Holding, iCoreConnect, Genius Group, Helius Medical Technologies, or TradeUP Acquisition?August 10, 2023 | finance.yahoo.comA Look At The Fair Value Of Genus plc (LON:GNS)July 23, 2023 | finance.yahoo.comGenus' (LON:GNS) earnings trajectory could turn positive as the stock climbs 4.9% this past weekMay 18, 2023 | msn.comPeel Hunt Limited Reiterates Genus (LSE:GNS) Buy RecommendationSeptember 23, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.May 16, 2023 | uk.investing.comFTSE 100 falls to fresh lows as wall Street makes weak startMay 15, 2023 | finance.yahoo.comShould Weakness in Genus plc's (LON:GNS) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?April 27, 2023 | finance.yahoo.comGenus plc (GNS.L)April 22, 2023 | benzinga.comGenius Gr Stock (AMEX:GNS), Short Interest ReportFebruary 23, 2023 | finance.yahoo.comGenus plc Interim results for the six months ended 31 December 2022February 13, 2023 | finance.yahoo.comGenus' (LON:GNS) investors will be pleased with their favorable 31% return over the last five yearsDecember 26, 2022 | finance.yahoo.comWith 80% ownership, Genus plc (LON:GNS) boasts of strong institutional backingNovember 17, 2022 | finance.yahoo.comHere's Why Genus plc's (LON:GNS) CEO Is Unlikely to Expect A Pay Rise This YearOctober 11, 2022 | finance.yahoo.comGenus' (LON:GNS) Dividend Will Be £0.217September 26, 2022 | reuters.comGNS.L - Genus plc | Stock Price & Latest News | ReutersSeptember 11, 2022 | finance.yahoo.comGenus (LON:GNS) Will Pay A Dividend Of £0.217September 9, 2022 | finance.yahoo.comEdited Transcript of GNS.L earnings conference call or presentation 8-Sep-22 6:01am GMTSeptember 9, 2022 | finance.yahoo.comEdited Transcript of GNS.L earnings conference call or presentation 8-Sep-22 9:30am GMTSeptember 8, 2022 | finance.yahoo.comGenus plc Reports Preliminary Results for the Year Ended 30 June 2022September 3, 2022 | washingtonpost.comThe unusual story behind a newly identified dinosaur's name - The Washington PostAugust 31, 2022 | finance.yahoo.comBanana Chips Market 2022-2028 | Global Opportunities, Challenges, Drivers, Trends, Key Players, Regional Segmentation, Types, Applications, Developments, Business Strategies - Yahoo FinanceAugust 25, 2022 | newsweek.comVegas Cops Rescue Roadrunner Trapped in Trash - NewsweekAugust 18, 2022 | nytimes.comHow the Chile Became Hot - The New York TimesSee More Headlines Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS CUSIPN/A CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees3,500Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 4,500 High Stock Price ForecastGBX 4,500 Low Stock Price ForecastGBX 4,500 Forecasted Upside/Downside+117.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.50 Trailing P/E Ratio4,148.00 Forward P/E Ratio25.16 P/E Growth2.87Net Income£33.30 million Net Margins4.83% Pretax MarginN/A Return on Equity5.58% Return on Assets3.75% Debt Debt-to-Equity Ratio40.92 Current Ratio1.76 Quick Ratio1.08 Sales & Book Value Annual Sales£689.70 million Price / Sales1.99 Cash FlowGBX 41.02 per share Price / Cash Flow50.56 Book ValueGBX 877 per share Price / Book2.36Miscellaneous Outstanding Shares66,030,000Free FloatN/AMarket Cap£1.37 billion OptionableNot Optionable Beta0.41 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Alison Jane Henriksen ACA (Age 56)CFO & Exec. Director Comp: $647kMr. Stephen David Wilson (Age 64)Exec. Director Comp: $880kMr. Jorgen Kokke (Age 54)Chief Exec. Officer & Director Dr. Matt CulbertsonChief Operating OfficerDr. Elena RiceHead of R&D and Chief Scientific OfficerMr. Daniel William David HartleyGroup Gen. Counsel & Company Sec.Ms. Angelle R. RosataGroup HR DirectorMr. Jerry ThompsonChief Operating Officer of Genus ABS BeefDr. Nate ZwaldChief Operating Officer of Genus ABS DairyMs. Janet DuaneGroup Financial ControllerMore ExecutivesKey CompetitorsOxford Nanopore TechnologiesLON:ONTErgomedLON:ERGOPureTech HealthLON:PRTCSilence TherapeuticsLON:SLNAvacta GroupLON:AVCTView All CompetitorsInsidersStephen WilsonSold 5,241 sharesTotal: £11.23 M ($2,142.00/share)Iain FergusonBought 1,000 shares on 5/16/2023Total: £2.48 M ($2,479.00/share)Alison HenriksenBought 1,658 shares on 2/23/2023Total: £4.97 M ($2,999.00/share)View All Insider Transactions GNS Stock - Frequently Asked Questions Should I buy or sell Genus stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNS shares. View GNS analyst ratings or view top-rated stocks. What is Genus' stock price forecast for 2023? 1 analysts have issued 12 month target prices for Genus' stock. Their GNS share price forecasts range from GBX 4,500 to GBX 4,500. On average, they expect the company's share price to reach GBX 4,500 in the next twelve months. This suggests a possible upside of 117.0% from the stock's current price. View analysts price targets for GNS or view top-rated stocks among Wall Street analysts. How have GNS shares performed in 2023? Genus' stock was trading at GBX 2,984 at the beginning of the year. Since then, GNS shares have decreased by 30.5% and is now trading at GBX 2,074. View the best growth stocks for 2023 here. How often does Genus pay dividends? What is the dividend yield for Genus? Genus declared a dividend on Thursday, September 7th. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 21.70 per share on Friday, December 8th. This represents a yield of 0.97%. The ex-dividend date is Thursday, November 9th. This is an increase from the stock's previous dividend of GBX 10.30. The official announcement can be viewed at this link. Read our dividend analysis for GNS. Is Genus a good dividend stock? Genus (LON:GNS) pays an annual dividend of GBX 32 per share and currently has a dividend yield of 1.47%. The dividend payout ratio is 6,400.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for GNS. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN). What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How do I buy shares of Genus? Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 2,074. How much money does Genus make? Genus (LON:GNS) has a market capitalization of £1.37 billion and generates £689.70 million in revenue each year. The company earns £33.30 million in net income (profit) each year or GBX 0.50 on an earnings per share basis. How many employees does Genus have? The company employs 3,500 workers across the globe. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The official website for the company is www.genusplc.com. The company can be reached via phone at +44-1256-347100. This page (LON:GNS) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.